TABLE 3.
Treatments in hospital
| Treatments | Duration of viral shedding | |||
|---|---|---|---|---|
| Total (n = 183) | <20 days (n = 86) | ≥20 days (n = 97) | P value | |
| Antibiotics | 137 (74.9%) | 54 (62.8%) | 83 (85.6%) | <0.001 |
| Antiviral treatment | ||||
| Arbidol | 173 (94.5%) | 85 (98.8%) | 88 (90.7%) | 0.020 |
| Oseltamivir | 117 (63.9%) | 41 (47.7%) | 76 (78.4%) | <0.001 |
| Lopinavir/Ritonavir | 159 (86.9%) | 72 (83.7%) | 87 (89.7%) | 0.232 |
| α‐interferon | 162 (88.5%) | 78 (90.7%) | 84 (86.6%) | 0.385 |
| Ribavirin | 6 (3.3%) | 1 (1.2%) | 5 (5.2%) | 0.216 |
| Corticosteroid | 70 (38.3%) | 18 (20.9%) | 52 (53.6%) | <0.001 |
| Duration (d)† | 4.0 (3.0‐6.0) | 4.5 (1.8‐7.0) | 4.0 (3.0‐6.0) | |
| Dose (mg/d)† | 43.3 (40.0‐74.4) | 60.0 (40.0‐80.0) | 40.0 (40.0‐63.2) | |
| Immunoglobulin | 31 (16.9%) | 5 (5.8%) | 26 (26.8%) | <0.001 |
| Oxygen support | 0.074 | |||
| Nasal cannula | 139 (76.0%) | 68 (79.1%) | 71 (73.2%) | |
| Mask | 19 (10.4%) | 8 (9.3%) | 11 (11.3%) | |
| NMV | 7 (3.8%) | 1 (1.2%) | 6 (6.2%) | |
| IMV | 4 (2.2%) | 1 (1.2%) | 3 (3.1%) | |
†For 70 patients who received corticosteroid; duration and dose were count before the first negative result of SARS‐CoV‐2 RNA; IMV, invasive mechanical ventilation; NMV, noninvasive mechanical ventilation.